Insider Selling and Institutional Ownership: A Closer Look at Recursion Pharmaceuticals
Recursion Pharmaceuticals (Nasdaq: RXRX) made headlines recently when its CEO, Christopher Gibson, sold over 56,000 shares of the company’s stock for over half a million dollars.
While Gibson still owns over 900,000 shares in the company, corporate insiders have sold over 118,000 shares of the company’s stock in the last 90 days. This may indicate that insiders believe that the company’s stock is overvalued and are taking advantage of the current market conditions.
In spite of this, hedge funds and institutional investors, who currently own over 60% of the stock, have recently adjusted their stakes, which suggests that there is ongoing interest in the company’s future prospects.
Recursion has a one-year low of $4.54 and a one-year high of $14.18, which indicates a significant price jump in the past year. Additionally, the company beat earnings estimates for the quarter by $0.01 per share, which is a positive sign for investors.
Analysts have also provided their opinions on the RXRX stock, with some suggesting that the company’s stock is currently overvalued and others stating that the company has strong growth potential in the long term.
Overall, Recursion Pharmaceuticals’ recent insider selling and institutional ownership highlights the importance of conducting thorough research before investing in a company’s stock.
About Recursion Pharmaceuticals
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.